Abstract
The surface glycoprotein CD44 is widely distributed in different tissues. In contrast to healthy tissue, tumour samples show a more complex pattern of CD44 expression, indicating a loss of splice control. Beside cell-surface expression, the measurement of soluble CD44 in serum of cancer patients could be useful in early diagnosis and assessment of disease status. We evaluated the surface expression of CD44 isoforms in 22 ovarian cancer patients by means of immunohistochemistry. Additionally, we investigated 134 serological samples of these patients for the occurrence of CD44 isoform expression. For CD44 standard, CD44v5 and CF44v6 mean serum levels in patients with clinically detectable or non-detectable ovarian cancer were 422.4 +/- 143.8 ng ml-1 and 547.4 +/- 148.2 ng ml-1, 12.3 +/- 7.9 ng ml-1 and 21.9 +/- 12.2 ng ml-1 and 105.5 +/- 37.9 ng ml-1 and 144.9 +/- 50.9 ng ml-1 respectively (P-values not significant). CD44 surface proteins containing epitopes encoded by splice variants CD44v5, CD44v6 and CD44v7-8 were immunohistochemically detected in 9% (n = 2), 13% (n = 3) and 4% (n = 1) of the 22 tumour samples respectively. In the present study we showed that in ovarian cancer CD44 isoforms CD44v5 and CD44v6 are expressed in very low amounts by the tumours. In accordance with this, we found that the presence of tumour is not associated with higher serum levels of CD44standard, CD44v5 and CD44v6 in preoperative serum samples in ovarian cancer patients.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sliutz, G., Tempfer, C., Winkler, S. et al. Immunohistochemical and serological evaluation of CD44 splice variants in human ovarian cancer. Br J Cancer 72, 1494–1497 (1995). https://doi.org/10.1038/bjc.1995.535
Issue Date:
DOI: https://doi.org/10.1038/bjc.1995.535
This article is cited by
-
MMP-14 and CD44 in Epithelial-to-Mesenchymal Transition (EMT) in ovarian cancer
Journal of Ovarian Research (2016)
-
Diagnostic accuracy of CD44V6 for osteosarcoma: a meta-analysis
Journal of Orthopaedic Surgery and Research (2016)
-
Prognostic significance of CD44V6 expression in osteosarcoma: a meta-analysis
Journal of Orthopaedic Surgery and Research (2015)
-
Evaluation of soluble CD44 protein marker to distinguish the premalignant and malignant carcinoma cases in cervical cancer patients
Medical Oncology (2014)
-
RETRACTED ARTICLE: Correlation of CD44v6 expression with ovarian cancer progression and recurrence
BMC Cancer (2013)